UK Next-generation Sequencing Market
UK Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031
UK NEXT-GENERATION SEQUENCING MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The UK next-generation sequencing market, valued at USD 0.73 billion in 2025, stood at USD 0.80 billion in 2026 and is projected to advance at a resilient CAGR of 14.8% from 2026 to 2031, culminating in a forecasted valuation of USD 1.59 billion by the end of the period. Next-generation Sequencing refers to non-Sanger-based, high-throughput DNA sequencing technologies. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. These technologies are designed to process large volumes of genomic data and can be used in various applications, such as clinical diagnostics, drug discovery & development, and agricultural research.
KEY TAKEAWAYS
-
By CountryThe UK is experiencing substantial growth in the Next-generation Sequencing market during the forecast period, driven by advancements in genomic research capabilities and increased funding.
-
By Product TypeBy product type, consumables segment is projected to reach USD 896.2 million by 2031, growing at a CAGR of 13.6% during the forecast period.
-
By ApplicationBy application, diagnostics are experiencing strong growth in the UK Next-generation Sequencing market at a CAGR of 15.2% during the forecast period.
-
Competitive Landscape - Star PlayersIllumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies were identified as leading players in the UK Next-generation Sequencing market, given their strong market presence and extensive product portfolios.
-
Competitive Landscape - StartupsSeveral innovative companies have distinguished themselves by securing strong positions in specialized areas, underscoring their potential as emerging contributors to the market.
The UK Next-generation Sequencing market is expanding rapidly, driven by advancements in sequencing platforms, growing clinical applications, and increasing integration of genomic solutions in healthcare. The NHS investment in genomic services, expanding precision medicine initiatives, and regulatory approvals for CRISPR-based therapies are further accelerating demand for high-performance sequencing technologies across the country.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The UK Next-generation Sequencing market is currently experiencing a phase of innovation and rapid adoption. Healthcare systems and research institutions across the UK are witnessing advancements in sequencing technology development and regulatory frameworks. This progress aligns with emerging trends in precision medicine, rare disease research, and genomic-based therapies. In the UK, the use of advanced sequencing platforms, long-read sequencing technologies, and multi-omics integration is increasing among hospitals, research centers, and diagnostic laboratories. These technologies facilitate comprehensive genetic analysis, promote faster diagnosis, enable personalized treatment approaches, and align with precision medicine and preventive care strategies. Government bodies and regulatory authorities are encouraging genomic research, the development of AI-enhanced data analysis tools, and public-private research and development programs. These initiatives help accelerate clinical adoption and promote the implementation of validated, clinically proven sequencing platforms tailored to the needs of the UK patient population.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Technological advancements in sequencing platforms
-
Significant funding and collaborations in genomic research and precision medicine
Level
-
High Capital Investment and Operational Costs
Level
-
Expanding applications in clinical diagnostics
Level
-
Data management and storage complexity
-
Shortage of Skilled Bioinformatics Professionals
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Technological advancements in sequencing platforms
Continuous advancements in next-generation sequencing platforms are significantly improving sequencing speed, accuracy, and throughput while reducing per-sample costs. Innovations such as high-throughput instruments, long-read sequencing, and improved automation are expanding the adoption of NGS across research and clinical settings in the UK, supporting large-scale genomic studies and precision medicine initiatives.
Restraint: High Capital Investment and Operational Costs
The adoption of NGS technologies requires substantial capital investment for sequencing instruments, laboratory infrastructure, and specialized reagents. In addition, ongoing operational costs related to maintenance, data analysis, and skilled personnel can be significant. These financial barriers may limit adoption, particularly among smaller laboratories and research institutions.
Opportunity: Expanding applications in clinical diagnostics
The expanding use of NGS in clinical diagnostics presents significant growth opportunities in the UK market. NGS is increasingly utilized for applications such as oncology testing, rare disease diagnosis, and infectious disease surveillance. Its ability to deliver comprehensive genomic insights supports improved disease detection, treatment selection, and personalized patient care.
Challenge: Data management and storage complexity
NGS technologies generate vast volumes of genomic data that require robust computational infrastructure for storage, processing, and analysis. Managing these large datasets while ensuring data security, regulatory compliance, and efficient interpretation presents a significant challenge for healthcare institutions and research organizations implementing NGS workflows.
UK NEXT-GENERATION SEQUENCING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Deployment of nanopore sequencing platforms in UK hospitals and public health laboratories to perform real-time genomic sequencing of SARS-CoV-2 for outbreak investigations and infection control | Enables rapid genomic surveillance and identification of transmission clusters, supporting faster infection control interventions in healthcare settings |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The UK Next-generation Sequencing market is a collaborative ecosystem where technology providers, healthcare institutions, research organizations, bioinformatics companies, and clinical professionals work together to develop and implement sequencing solutions in healthcare and research. Companies in the UK supply a variety of sequencing products, including platforms, consumables, and bioinformatics tools. Contract research organizations, diagnostic service providers, and academic institutions support the research, clinical validation, and implementation stages for these sequencing technologies. Ultimately, healthcare institutions and research centers across the UK utilize the developed sequencing solutions, benefiting from supportive regulatory frameworks and funding initiatives.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
UK Next-generation Sequencing Market, by Product
The product segment dominated the market in 2025, with sequencing platforms, consumables, and bioinformatics tools being essential components of sequencing workflows used regularly in research and clinical settings. This is due to their technological capabilities, throughput performance, and proven reliability, making them preferred for genomic research and clinical diagnostics.
UK Next-generation Sequencing Market, by Application
Diagnostics represented significant segments of the UK Next-generation Sequencing market. The increasing application of genomic testing in disease diagnosis and treatment selection has positioned this segment prominently in the country. Factors such as growing awareness of genetic diseases, expanding cancer genomics programs, rare disease initiatives, and personalized medicine approaches are driving the demand for sequencing-based diagnostics.
UK NEXT-GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX
Illumina, recognized as a leading player in the UK Next-generation Sequencing market, offers a comprehensive portfolio that includes sequencing platforms, consumables, and bioinformatics solutions for clinical and research applications. The company maintains a strong presence in the UK market and collaborates with healthcare providers, research institutions, and diagnostic laboratories. Another significant player in the UK market is Oxford Nanopore Technologies, identified as an important contributor. The company is strengthening its position by introducing long-read sequencing platforms, portable sequencing devices, and specialized solutions designed for use in genomic research, clinical diagnostics, and field-based applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific (US)
- Oxford Nanopore Technologies plc. (UK)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- PacBio (US)
- Eurofins Scientific (Luxembourg)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 733.7 Million |
| Market Forecast in 2031 (Value) | USD1,587.2 Million |
| Growth Rate | CAGR of 14.8% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Country Covered | UK |
| Parent & Related Segment Reports |
Next generation Sequencing Market North America Next Generation Sequencing Market Europe Next Generation Sequencing Market Asia Pacific Next Generation Sequencing Market Germany Next Generation Sequencing Market France Next Generation Sequencing Market Single-molecule Real-time (SMRT) Sequencing Market South Korea Next-Generation Sequencing Market China Next Generation Sequencing Market Next Generation Sequencing Services Market |
WHAT IS IN IT FOR YOU: UK NEXT-GENERATION SEQUENCING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Understanding adoption patterns for Next-generation Sequencing across UK healthcare and research institutions | Assessed sequencing technology usage trends across key UK healthcare providers, research institutions, and diagnostic laboratories, highlighting differences in adoption of short-read and long-read platforms across oncology, rare disease, infectious disease, and population genomics applications | Helps clients align product portfolios with application-specific requirements, funding priorities, and clinical implementation pathways |
| Identifying local service providers and collaboration opportunities | Mapped UK-based sequencing service providers, bioinformatics companies, and research collaborators, with insights into genomic data analysis capabilities, clinical validation services, and research partnership models | Supports market entry strategies, enables collaboration opportunities, improves service delivery models, and accelerates clinical adoption |
RECENT DEVELOPMENTS
- November 2025 : Oxford Nanopore Technologies in collaboration with bioMérieux launched AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology.
- April 2025 : Oxford Nanopore Technologies has expanded its Compatible Products Programme to include partners such as Agilent and Thermo Fisher Scientific, among others. The initiative enhances integration across library prep, automation, and single-cell workflows, strengthening ONT’s multi-omics ecosystem and user flexibility.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study on the UK Next-generation Sequencing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the UK Next-generation Sequencing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the UK Next-generation Sequencing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the UK Next-generation Sequencing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the next-generation sequencing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the next-generation sequencing market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players in the UK Next-generation Sequencing market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the UK Next-generation Sequencing market
- To benchmark players within the UK Next-generation Sequencing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the UK Next-generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in UK Next-generation Sequencing Market